hepatitis C
NICE to recommend three new treatments for hep C
October 16, 2015Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C
NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …
FDA sued over failure to disclose Sovaldi data
June 30, 2015Sales and Marketing FDA, Gilead, hepatitis C, sofosbuvir, sovaldi
Two groups that campaign for wider access to medicines have filed a lawsuit against the FDA, in a bid to …
The Pharmafocus debate: Is the price of new hepatitis C treatments fair?
April 27, 2015Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi
YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …
Gilead presents new Sovaldi data
April 23, 2015Sales and Marketing GS-5816, GS-9857, Gilead, NS3/4A, SVR12, hepatitis C, sofosbuvir, sovaldi
Gilead is looking to several new studies to support future new Sovaldi combinations and broadened treatment groups for its hepatitis …
AbbVie hep C drug gets priority review in Japan
April 16, 2015Sales and Marketing AbbVie, EC, EU, Europe, Exviera, FDA, Japan, Viekira Pak, Viekirax, hepatitis C, ombitasvir/paritaprevir/ritonavir
AbbVie’s combination hepatitis C treatment looks set to be approved in yet another country after being granted priority review in …
BMS resubmits hepatitis C drug
March 13, 2015Sales and Marketing BMS, NDA, daclatasvir gilead, hepatitis C, sovaldi
Bristol-Myers Squibb has resubmitted its hepatitis C (HCV) treatment for FDA approval despite previously backing out, as it spots a …
NICE recommends Harvoni for hepatitis C
March 3, 2015Sales and Marketing Gilead, NICE, harvoni, hepatitis C, ledipasvir-sofosbuvir
NICE has signalled a provisional OK for Gilead’s Harvoni to be used as a treatment for hepatitis C by the …
New drug added to generic Sovaldi licensing
January 26, 2015Manufacturing and Production, Sales and Marketing Gilead, HCV, hepatitis C, sofosbuvir, sovaldi
Gilead has expanded the licensing of generic versions of its blockbuster hepatitis C treatment Sovaldi to include a new experimental …
Global drug spending set to top $1 trillion
November 20, 2014Sales and Marketing Gilead, IMS, Kadcyla, Perjeta, drugs, hepatitis C, sovaldi, spend
Worldwide spending on drugs will reach over $1 trillion in 2014 and $1.3 trillion by 2018, according to a new …
BMS claims advance with hepatitis C regimen
November 10, 2014Research and Development, Sales and Marketing BMS, Gilead, HCV, dcv-trio, hep C, hepatitis C, liver, sovaldi
Bristol-Myers Squibb has reported data for its hepatitis C virus cocktail that it says outperforms even newer all-oral therapies in …
Gilead allows generic prices for Sovaldi
September 16, 2014Manufacturing and Production, Sales and Marketing Gilead, hep C, hepatitis C, sofosbuvir, sovaldi
Gilead will allow Indian generic drug firms to make cheap copies of its new hepatitis C pill Sovaldi in an …
Sovaldi scores in HIV patients
July 21, 2014Sales and Marketing Gilead, HIV, JAMA, hep C, hepatitis C, sovaldi
Patients with HIV and hepatitis C virus (HCV) have responded well to a combination of Gilead Sciences’ Sovaldi and ribavirin …
New drugs see J&J sales rise
July 17, 2014Medical Communications, Sales and Marketing J&J, JJ, Q2, hepatitis C, olysio, sovaldi
Johnson & Johnson saw sales rise 9.1% to $19.5 billion year on year on the back of a strong performance …
Gilead price lambasted by US health insurers
May 21, 2014Medical Communications, Sales and Marketing Gilead, Incivek, Victrelis, hepatitis C, sovaldi
Gilead’s new hepatitis C pill Sovaldi is coming under more pressure in the US as health insurers hit out at …
Europe approves Janssen’s hep C drug Olysio
May 20, 2014Research and Development, Sales and Marketing Janssen, hepatitis C, sovaldi
Janssen-Cilag International’s Olysio has been given marketing authorisation in the European Union for the treatment of adults with hepatitis C …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
